CHC
- Address
- lock Available on a paid plan
Digestive System Diseases
The research team at CHC focuses on innovative treatments for inflammatory bowel conditions, including ulcerative colitis and Crohn’s disease. Studies aim to evaluate new drug candidates and biological strategies to reduce disease activity and prevent postoperative recurrence.
- Ulcerative colitis – novel oral therapy evaluation
- Crohn’s disease – postoperative biological treatment strategies
- Endoscopic recurrence monitoring after ileocolonic resection
The department leverages its expertise in gastroenterology to advance patient‑centered care and improve long‑term outcomes for individuals living with chronic digestive disorders.
Respiratory Tract Diseases
At CHC, investigators are exploring therapies to protect the lungs of extremely preterm infants at risk of Bronchopulmonary Dysplasia. Projects assess the safety of intratracheal EXOB-001 and the potential of mesenchymal‑derived extracellular vesicles to prevent this severe neonatal lung disease.
- Bronchopulmonary Dysplasia – prevention with mesenchymal extracellular vesicles
- Safety assessment of intratracheal EXOB-001 in preterm newborns
- Neonatal lung injury therapeutic development
The respiratory research program integrates neonatal intensive care expertise to develop safer, more effective interventions for vulnerable newborns.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Exo Biologics1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHC
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A single arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis. | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Recruiting | Aug 2023 | Dec 2024 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abbv-668 | 1 | Unknown | 2023-08-10 | 2023-08-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.